Heart Protection Study Collaborative Group. Effects on 11year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high risk individuals: A randomised controlled trial. Lancet 2011; 387:201320.
Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis 2007;24(23):17082.
Collins R, Armitage J, Parish S et al (HPS). Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other highrisk conditions. Lancet 2004 Mar 6;363(9411):75767.
Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet 2012 Aug 11;380(9841):58190.
Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; 1 (CD004816).
Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L et al. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet 2008 Jan 12;371(9607):11725.
Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta analysis. Lancet 2010; 375:187584.
Ray KK, Seshasai SR, Erqou S et al. Statins and all-cause mortality in highrisk primary prevention: a metaanalysis of 11 randomized control led trials involving 65,229 participants. Arch Intern Med 2010;170(12):102431.
Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: metaanalysis of randomised controlled trials. BMJ. 2009;338:b2376. doi:10.1136/bmj.b2376.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering in 20 536 highrisk individuals: a randomized placebocontrolled trial. Lancet 2002;360:722.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.
Armitage J, Bowman L, Wallendszus K et al (SEARCH). Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a doubleblind randomised trial. Lancet 2010 Nov 13;376(9753):165869.
Emberson J, Bennett D, Link E et al. Creactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Lancet 2011 Feb 5;377(9764):46976.
Afilalo J, Duque G, Steele R et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta analysis. J Am Cardiol 2008;51(1):3745.
Ridker PM, Danielson E, Fonseca FA et al (JUPITER). Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med 2008;359(21):2195207.
Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495504.
Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDARECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.J Am Coll Cardiol 2009;54:55865.
Patti G, Cannon CP, Murphy SA et al. Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention/ Clinical Perspective: A Collaborative Patient Level MetaAnalysis of 13 Randomized Studies. Circulation 2011;123:16221632.
Kastelein JJ, Akdim F, Stroes ES et al (ENHANCE). Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358(14):143143.
Rossebø AB, Pedersen TR, Boman K et al (SEAS). Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359(13):134356.
Baigent C, Landray MJ, Reith C et al (SHARP). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. Lancet 2011 Jun 25;377(9784):218192.
Boden WE, Probstfield JL, Anderson T et al (AIMHIGH). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011 Dec 15;365(24):225567.
Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta analysis of randomized statins trials. Lancet 2010; 375:73542.
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive dose compared with moderate dose statin therapy. A Metaanalysis. JAMA 2011;305:255664.
Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M et al. Metaanalysis of drug induced adverse events associated with intensivedose statin therapy. Clin Therapy 2007 Feb;29(2):25360.
Kjekshus J, Apetrei E, Barrios V et al (CORONA). Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357(22):2248 61.
Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(8A):77C81C.
Amarenco P, Bogousslavsky J, Callahan A et al (SPARCL). Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355(6):54959.
Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120(4):83343.
Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a metaanalysis. JAMA 2006;295(1):7480.
The effects of cholesterol lowering with simvastatin on causespecific mortality and on cancer incidence in 20,536 highrisk people: a randomised placebocontrolled trial. BMC Med 2005;3:6.
Christopher P. Cannon, M.D., Michael A. Blazing, M.D., Robert P. Giugliano, M.D et al. Ezetimibe Added to Statin Therapy after Acute Coro nary Syndromes. N Engl J Med 2015; 372:23872397.
Att förebygga aterosklerotisk hjärtkärlsjukdom med läkemedel – behandlingsrekommendation Information från Läkemedelsverket 2014:(25) 5
HOPE3 Yusuf S, et al. ”Blood Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease”. The New England Journal of Medicine. 2016. 374(21):20322343
Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. Epub 17 mar 2017. doi: 10.1056/NEJMoa1615664.
Schwartz et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syn drome. N Engl J Med. 2018;379(22):2097107.